Five new IPOs are scheduled for the week of May 13th. The full IPO calendar is here.
Here's a listing of this week's new IPOs, ranked by size of IPO.
Midstream gas LP: Tallgrass Energy Partners, LP (NYSE:TEP)
Based in Overland Park, KS, Tallgrass Energy Partners, LP scheduled a $287 million IPO with a market capitalization of $891 million at a price range mid-point of $22, for Tuesday, May 14, 2013.
TEP provides natural gas transportation and storage services for customers in the Rocky Mountain and Midwest regions of the United States.
TEP is a spin-off of a $3.1 billion acquisition by TheTallgrass Group from Kinder Morgan Energy Partners, L.P. (NYSE: KMP), in November, 2012. The Tallgrass Group is based in Overland Park, KS.
Homebuilder: William Lyon Homes (NYSE:WLH)
Based in Newport Beach, CA, William Lyon Homes scheduled a $200 IPO with a market capitalization of $708 million at a price range mid-point of $23, for Wednesday, May 15, 2013.
WLH is a California-based homebuilder that came out of Chapter 11 bankruptcy in February, 2012, and owns or controls over 10,000 homebuilding lots.
Business analytics software: Tableau Software (NYSE:DATA)
Based in Seattle, WA, Tableau Software scheduled a $176 million IPO with a market capitalization of $1.4 billion at a price range mid-point of $24.50, for Friday, May 17, 2013.
On a year-over-year basis DATA's sales increased 82% in 2011, 106% in 2012 and 60% in the March '13 quarter. DATA had been making marginal profits which turned in to loss for the March '13 quarter, because sales & marketing jumped to $24 million from $11 million.
Cloud-based marketing: Marketo (NASDAQ:MKTO)
Based in San Mateo, CA, Marketo scheduled a $73 million IPO with a market capitalization of $429 at a price range mid-point of $12, for Friday, May 16, 2013.
MKTO provides a cloud-based marketing software platform, similar to Eloqua, which was recently acquired by Oracle for $871 million. MKTO's subscription dollar retention rate was 100% for each of 2011 and 2012.
Biopharma: Ambit Biosciences (NASDAQ:AMBI)
Based in San Diego, CA, Ambit Biosciences scheduled a $65 million IPO with a market capitalization of $180 million at a price range mid-point of $14 for Wednesday, May 15, 2013.
AMBI is a cancer-oriented biopharma company. Collaboration agreements are winding down, including the one that generated all of AMBI's March 2013 quarter revenue.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.